Cybernetic Adversarial Networks (CAN)—GenAI serving as Oracle rigorously validating human hypotheses instead of just generating them—inverts the typical GAN workflow and unlocks massive scientific value.
#GenAI#LifeSciences#DeepLearning
https://t.co/j9jEDGx6b1
712 North Inc. announced on November 11, 2025, that a new patent was granted by the #USPTO.
712 North develops personalized mitochondrial medicines for patients with Alzheimer’s and other age-related diseases. For more information, please visit https://t.co/30cP5X4Cc4.
Delighted to see experimental confirmation of our OPA1 model after 13 years!
Researchers showed last week that OPA1 can shape cardiolipin-rich membranes, something we proposed over a decade ago. https://t.co/FGg8bGbWIF
Keep up @altos_labs@EPFL_en@CUBoulder@nyuniversity!
A flood of AI-fabricated research is overwhelming science.
Instead of fearing AI, we must integrate it as an independent 3rd peer reviewer to fight fire with fire.
https://t.co/RZ1q662D0T
#ArtificialIntelligence#Science#GoldStandard
https://t.co/LCkbGs5I3v
Ask what you can do for your country…
AI as peer reviewer is a blueprint for improving research integrity in alignment with President Trump's "Restoring Gold Standard Science" executive order:
https://t.co/EopW4znfZv
#ArtificialIntelligence#Science#ReproducibilityCrisis#NIH
We need to build an unreasonable AI!
I invite interested computational and biomedical scientists to join me in this challenge.
#artificialintelligence#science#unreasonableAI
The Case for an Unreasonable AI. https://t.co/Dv2y2jfk60
Check out my op-ed about new applications for AI in the biopharmaceutical realm.
#ArtificialIntelligence#Biotec#DrugDiscover
AI, GIGO, and the biopharmaceutical venture. https://t.co/2I6z3VBWVL
Join NIA and partners on June 15 for the #AlzScience Twitter Chat! The chat will cover recent advances in #Alzheimers research, resources for researchers, #ClinicalTrials, and exciting things to look for in the future! Details: https://t.co/zJzyogFpl5
A comprehensive review by @712North in #PharmacolRes @ELSpharma focuses on “Recent advances in, and challenges of, designing OMA1 drug screens.” OMA1 is a membrane protease with relevance for complex diseases, such as #Alzheimer’s #cancer and #heart disease.